Article Text

other Versions

Download PDFPDF
Impact of fampridine on quality of life: clinical benefit in real-world practice
  1. María Belén Marzal-Alfaro1,
  2. María Luisa Martín Barbero1,
  3. JoseM García Domínguez2,
  4. Fernando Romero-Delgado2,
  5. María Luisa Martínez Ginés2,
  6. Ana Herranz1,
  7. María Sanjurjo-Sáez1
  1. 1Pharmacy Department, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain
  2. 2Neurology Department, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain
  1. Correspondence to María Belén Marzal-Alfaro, Servicio de Farmacia, Hospital General Universitario Gregorio Marañón, Calle Doctor Esquerdo, 46, Madrid 28007, Spain; belen.marzal{at}


Objectives To assess the effectiveness and tolerability of fampridine in patients with multiple sclerosis (MS) in real clinical practice and to analyse adherence to treatment and general satisfaction of patients in terms of quality of life (QOL).

Methods Patients who started treatment with fampridine from May 2014 to October 2014 were included. Primary and secondary outcomes were Timed 25-Foot Walk (T25FW) and MS Walking Scale-12 (MSWS-12) respectively, measured at baseline and 2 weeks, 3 and 6 months. Adherence was measured by the Morisky–Green questionnaire, patient satisfaction with a visual analogue scale (VAS) and QOL with improvement in mobility, self-care, daily activities, pain/discomfort or anxiety/depression.

Results 30 patients (46.7% women) of mean age 39 years, mean MS duration 13.7 years, mean Expanded Disability Status Scale score 5.8, 57% with relapsing-remitting MS were included. 22 patients (73%) continued to take treatment throughout the study period. Two weeks after treatment initiation all measures improved significantly from baseline (T25FW: −7.5 s, p<0.05; MSWS-12: −36.7, p<0.05). At 6 months, walking speed and self-perceived walking ability were significantly improved (T25FW: −3.8 s, p<0.05; MSWS-12: −30.0, p<0.05). Adverse events were reported by 30% of patients. Seizures were registered in one patient. 70% of patients were adherent with treatment. Median (IQR) general satisfaction VAS score was 8 (7–9). Patients reported an improvement in mobility (70%), anxiety/depression (33.3%), self-care (23.3%), daily activities (23.3%) and pain/discomfort (3.3%).

Conclusions Fampridine is effective and safe in patients with MS in real clinical practice up to 6 months. Adherence to treatment was suboptimal but patients' general satisfaction was high and fampridine improved several items of QOL.

  • Walking ability
  • Fampridine
  • adherence
  • quality of life
  • multiple sclerosis

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.